|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Schwartz M and Mazzaferro V:
Resection and liver transplantation for hepatocellular carcinoma.
Semin Liver Dis. 25:181–200. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruix J, Raoul JL, Sherman M, Mazzaferro
V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M,
Sangiovanni A, et al: Efficacy and safety of sorafenib in patients
with advanced hepatocellular carcinoma: Subanalyses of a phase III
trial. J Hepatol. 57:821–829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gish RG, Finn RS and Marrero JA: Extending
survival with the use of targeted therapy in the treatment of
hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 9 4 Suppl
2:S1–S24. 2013.
|
|
5
|
Llovet JM, Villanueva A, Lachenmayer A and
Finn RS: Advances in targeted therapies for hepatocellular
carcinoma in the genomic era. Nat Rev Clin Oncol. 12:408–424. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mancuso A, Mazzarelli C, Perricone G and
Zavaglia C: Sorafenib efficacy for treatment of HCC recurrence
after liver transplantation is an open issue. J Hepatol.
60:6812014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Darweish MM, Abbas A, Ebrahim MA and
Al-Gayyar MM: Chemopreventive and hepatoprotective effects of
Epigallocatechin-gallate against hepatocellular carcinoma: Role of
heparan sulfate proteoglycans pathway. J Pharm Pharmacol.
66:1032–1045. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee SI, Kim HJ and Boo YC: Effect of green
tea and (−)-epigallocatechin gallate on ethanol-induced toxicity in
HepG2 cells. Phytother Res. 22:669–674. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shimizu M, Shirakami Y, Sakai H, Tatebe H,
Nakagawa T, Hara Y, Weinstein IB and Moriwaki H: EGCG inhibits
activation of the insulin-like growth factor (IGF)/IGF-1 receptor
axis in human hepatocellular carcinoma cells. Cancer Lett.
262:10–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jin J, Chang Y, Wei W, He YF, Hu SS, Wang
D and Wu YJ: Prostanoid EP1 receptor as the target of
(−)-epigallocatechin-3-gallate in suppressing hepatocellular
carcinoma cells in vitro. Acta Pharmacol Sin. 33:701–709. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zapf MA, Kothari AN, Weber CE, Arffa ML,
Wai PY, Driver J, Gupta GN, Kuo PC and Mi Z: Green tea component
epigallocatechin-3-gallate decreases expression of osteopontin via
a decrease in mRNA half-life in cell lines of metastatic
hepatocellular carcinoma. Surgery. 158:1039–1048. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hernaádez-García S, González V, Sanz E and
Pandiella A: Effect of oncoxin oral solution in her2-overexpressing
breast cancer. Nutr Cancer. 67:1159–1169. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hollman PC, Feskens EJ and Katan MB: Tea
flavonols in cardiovascular disease and cancer epidemiology. Proc
Soc Exp Biol Med. 220:pp. 198–202. 1999; View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu L, Hudgins WR, Shack S, Yin MQ and
Samid D: Cinnamic acid: A natural product with potential use in
cancer intervention. Int J Cancer. 62:345–350. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang CS, Chung JY, Yang G, Chhabra SK and
Lee MJ: Tea and tea polyphenols in cancer prevention. J Nutr. 130
2S Suppl:S472–S478. 2000.
|
|
17
|
Gomez EV, Perez YM, Sanchez HV, Forment
GR, Soler EA, Bertot LC, Garcia AY, del Rosario Abreu Vazquez M and
Fabian LG: Antioxidant and immunomodulatory effects of Viusid in
patients with chronic hepatitis C. World J Gastroenterol.
16:2638–2647. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Al-Mahtab M, Akbar S, Khan M and Rahman S:
Increased survival of patients with end-stage hepatocellular
carcinoma due to intake of ONCOXIN®, a dietary supplement. Indian J
Cancer. 52:443–446. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Uddin MAI Dayem, Mahmood I, Ghosha AK and
Khatuns RA: Findings of the 3-Month supportive treatment with
ocoxin solution beside the standard modalities of patients with
different neoplastic diseases. TAJ. 22:172–175. 2009.
|
|
20
|
Diaz-Rodríguez E, Hernández-García S, Sanz
E and Pandiella A: Antitumoral effect of Ocoxin on acute myeloid
leukemia. Oncotarget. 7:6231–6242. 2016.PubMed/NCBI
|
|
21
|
Díaz-Rodríguez E and Pandiella A:
Multisite phosphorylation of Erk5 in mitosis. J Cell Sci.
123:3146–3156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Seoane S, Montero JC, Ocaña A and
Pandiella A: Breast cancer dissemination promoted by a
neuregulin-collagenase 3 signalling node. Oncogene. 35:2756–2765.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
de Alava E, Ocaña A, Abad M, Montero JC,
Esparís-Ogando A, Rodríguez CA, Otero AP, Hernández T, Cruz JJ and
Pandiella A: Neuregulin expression modulates clinical response to
trastuzumab in patients with metastatic breast cancer. J Clin
Oncol. 25:2656–2663. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoshikawa M, Ono N, Yodono H, Ichida T and
Nakamura H: Phase II study of hepatic arterial infusion of a
fine-powder formulation of cisplatin for advanced hepatocellular
carcinoma. Hepatol Res. 38:474–483. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alberts SR, Reid JM, Morlan BW, Farr GH
Jr, Camoriano JK, Johnson DB, Enger JR, Seay TE and Kim GP:
Gemcitabine and docetaxel for hepatocellular carcinoma: A phase II
north central cancer treatment group clinical trial. Am J Clin
Oncol. 35:418–423. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yata Y, Xue F, Takahara T, Kudo H, Hirano
K, Yasumura S, Minemura M, Scanga AE and Sugiyama T: Docetaxel
inhibits progression of human hepatoma cell line in vitro and is
effective in advanced hepatocellular carcinoma. Hepatol Res.
40:304–310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jordan MA, Thrower D and Wilson L: Effects
of vinblastine, podophyllotoxin and nocodazole on mitotic spindles.
Implications for the role of microtubule dynamics in mitosis. J
Cell Sci. 102:401–416. 1992.PubMed/NCBI
|
|
28
|
Muto Y, Moriwaki H, Ninomiya M, Adachi S,
Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, et
al: Prevention of second primary tumors by an acyclic retinoid,
polyprenoic acid, in patients with hepatocellular carcinoma.
Hepatoma Prevention Study Group. N Engl J Med. 334:1561–1567. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Takayama T, Sekine T, Makuuchi M, Yamasaki
S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi
Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical
recurrence rates of hepatocellular carcinoma: A randomised trial.
Lancet. 356:802–807. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Y, Duan W, Owusu L, Wu D and Xin Y:
Epigallocatechin-3-gallate induces the apoptosis of hepatocellular
carcinoma LM6 cells but not non-cancerous liver cells. Int J Mol
Med. 35:117–124. 2015.PubMed/NCBI
|
